Gene therapy in neuronopathic lysosomal storage disorders.

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Lysosomal storage disorders (LSDs) are inherited conditions caused by enzyme deficiencies, affecting multiple body systems.
• Neuronopathic LSDs specifically cause neurodegeneration, presenting significant challenges, particularly in pediatric populations.
• Despite individual rarity, these disorders collectively represent a notable burden, driving therapeutic innovation.

Purpose of the Study:

• To review the current landscape of gene and cell-based therapies for neuronopathic lysosomal storage disorders.
• To compare adeno-associated virus (AAV) and lentiviral vector approaches in gene therapy.
• To discuss the progress, challenges, and future directions in developing and delivering these advanced therapies.

Main Methods:

• Review of existing literature on gene and cell therapies for LSDs.
• Comparative analysis of AAV and lentiviral gene delivery systems.
• Discussion of clinical application, therapeutic development, and collaborative strategies.

Main Results:

• Gene and cell therapies are promising for treating severe pediatric LSD phenotypes.
• AAV and lentiviral vectors show distinct advantages and disadvantages for gene therapy applications.
• Significant progress has been made, but challenges remain in widespread patient access and therapeutic efficacy.

Conclusions:

• Combined therapeutic strategies and increased collaboration are crucial for advancing LSD treatments.
• Addressing delays in therapeutic development is essential for bringing innovative treatments to patients.
• Future efforts should focus on optimizing delivery and fostering interdisciplinary partnerships to overcome therapeutic hurdles.